PURPOSE: To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. PATIENTS AND METHODS: Patients were randomly assigned 1:1 to receive docetaxel/prednisone either with (arm A) or without (arm B) OGX-011 640 mg intravenously weekly. The primary end point was the proportion of patients with a prostate-specific antigen (PSA) decline of ≥ 50% from baseline, with the experimental therapy being considered of interest if the proportion of patients with a PSA decline was more than 60%. Secondary end points were objective response rate, progression-free survival (PFS), overall survival (OS), and changes in serum clusterin. RESULTS:Eighty-two patients were accrued, 41 to each arm. OGX-011 adverse effects included rigors and fevers. After cycle 1, median serum clusterin decreased by 26% in arm A and increased by 0.9% in arm B (P < .001). PSA declined by ≥ 50% in 58% of patients in arm A and 54% in arm B. Partial response occurred in 19% and 25% of patients in arms A and B, respectively. Median PFS and OS times were 7.3 months (95% CI, 5.3 to 8.8 months) and 23.8 months (95% CI, 16.2 months to not reached), respectively, in arm A and 6.1 months (95% CI, 3.7 to 8.6 months) and 16.9 months (95% CI, 12.8 to 25.8 months), respectively, in arm B. Baseline factors associated with improved OS on exploratory multivariate analysis were an Eastern Cooperative Oncology Group performance status of 0 (hazard ratio [HR], 0.27; 95% CI, 0.14 to 0.51), presence of bone orlymph node metastases only (HR, 0.45; 95% CI, 0.25 to 0.79), and treatment assignment to OGX-011 (HR, 0.50; 95% CI, 0.29 to 0.87). CONCLUSION: Treatment with OGX-011 and docetaxel was well tolerated with evidence of biologic effect and was associated with improved survival. Further evaluation is warranted.
RCT Entities:
PURPOSE: To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. PATIENTS AND METHODS: Patients were randomly assigned 1:1 to receive docetaxel/prednisone either with (arm A) or without (arm B) OGX-011 640 mg intravenously weekly. The primary end point was the proportion of patients with a prostate-specific antigen (PSA) decline of ≥ 50% from baseline, with the experimental therapy being considered of interest if the proportion of patients with a PSA decline was more than 60%. Secondary end points were objective response rate, progression-free survival (PFS), overall survival (OS), and changes in serum clusterin. RESULTS: Eighty-two patients were accrued, 41 to each arm. OGX-011 adverse effects included rigors and fevers. After cycle 1, median serum clusterin decreased by 26% in arm A and increased by 0.9% in arm B (P < .001). PSA declined by ≥ 50% in 58% of patients in arm A and 54% in arm B. Partial response occurred in 19% and 25% of patients in arms A and B, respectively. Median PFS and OS times were 7.3 months (95% CI, 5.3 to 8.8 months) and 23.8 months (95% CI, 16.2 months to not reached), respectively, in arm A and 6.1 months (95% CI, 3.7 to 8.6 months) and 16.9 months (95% CI, 12.8 to 25.8 months), respectively, in arm B. Baseline factors associated with improved OS on exploratory multivariate analysis were an Eastern Cooperative Oncology Group performance status of 0 (hazard ratio [HR], 0.27; 95% CI, 0.14 to 0.51), presence of bone or lymph node metastases only (HR, 0.45; 95% CI, 0.25 to 0.79), and treatment assignment to OGX-011 (HR, 0.50; 95% CI, 0.29 to 0.87). CONCLUSION: Treatment with OGX-011 and docetaxel was well tolerated with evidence of biologic effect and was associated with improved survival. Further evaluation is warranted.
Authors: Carsten-H Ohlmann; Axel S Merseburger; Henrik Suttmann; David Schilling; Lutz Trojan; Carsten Kempkensteffen; Stefan Corvin; Michael J Mathers; Patrick J Bastian Journal: World J Urol Date: 2011-11-20 Impact factor: 4.226
Authors: Fred Saad; Sebastien Hotte; Charles Catton; Darrel Drachenberg; Antonio Finelli; Neil Fleshner; Martin Gleave; Anil Kapoor; Wassim Kassouf; Andrew Loblaw; Scott North; Nawaid Usmani; Kim N Chi Journal: Can Urol Assoc J Date: 2013 Jul-Aug Impact factor: 1.862
Authors: Weiya Liu; George A Vielhauer; Jeffrey M Holzbeierlein; Huiping Zhao; Suman Ghosh; Douglas Brown; Eugene Lee; Brian S J Blagg Journal: Mol Pharmacol Date: 2015-05-04 Impact factor: 4.436
Authors: Fred Saad; Kim N Chi; Antonio Finelli; Sebastien J Hotte; Jonathan Izawa; Anil Kapoor; Wassim Kassouf; Andrew Loblaw; Scott North; Ricardo Rendon; Alan So; Nawaid Usmani; Eric Vigneault; Neil E Fleshner Journal: Can Urol Assoc J Date: 2015 Mar-Apr Impact factor: 1.862